Company intelligence / Profile preview

OCU L&C

Englewood Cliffs, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

OCU L&C is the U.S. subsidiary of Korean ophthalmic medical device developer Oculight. The entity was established in 2019 to serve as Oculight's platform for U.S. expansion and is focused on commercialization of the company's ophthalmic surgical products in the United States. Its lead product focus is iChopper, an ophthalmic surgical endoilluminator with a chopping function intended to improve intraoperative visibility during cataract surgery. Based on publicly available information, OCU L&C appears to function primarily as a commercial and market-entry vehicle rather than a standalone drug-development biotech company.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Selected local U.S. commercialization partners

Beyond the preview

Go deeper on OCU L&C.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCU L&C.

Explore the full profile